{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:52:39Z","timestamp":1772160759530,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,12,25]],"date-time":"2015-12-25T00:00:00Z","timestamp":1451001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>\n                      Sofosbuvir is widely prescribed for treatment of\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      infection. We compared the sustained virologic response rates (\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      12) and the haematologic toxicity of various sofosbuvir\u2010based regimens in routine clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used\n                      <jats:styled-content style=\"fixed-case\">ERCHIVES<\/jats:styled-content>\n                      (Electronically Retrieved Cohort of\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      infected Veterans) to identify\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      \u2010infected persons initiated on sofosbuvir\u2010based regimens. Treatment duration and regimen were defined as per labelling guidelines. We excluded persons with\n                      <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\n                      , positive hepatitis\u2010B surface antigen, hepatocellular carcinoma and missing\n                      <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4257 sofosbuvir\u2010treated persons, sofosbuvir\/simeprevir (30%), sofosbuvir\/ledipasvir (29%) and sofosbuvir\/ribavirin (23%) were the most common combinations prescribed. The mean age (\n                      <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>\n                      ) was 60.22 (6.3) years, 96% were male, 22.4% were black, 37.2% had cirrhosis, 29.7% were treatment\u2010experienced; baseline mean\n                      <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content>\n                      was 6.73 log l\n                      <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\n                      \/ml. Comorbidities included: 40.2% alcohol abuse or dependence, 39.7% drug abuse or dependence, 25.1% diabetes and 14.4% stage 3\u20135 chronic kidney disease. Overall, 86.7% completed a full course of treatment. Overall,\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      12 rates were 88\u201398% in the sofosbuvir\/simeprevir group and 93\u201398% in the sofosbuvir\/ledipasvir group and did not vary based on previous treatment history or cirrhosis at baseline. For genotype 2\/3 patients treated with sofosbuvir\/ribavirin,\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      12 rates ranged from 69 to 87% with lowest rates in treatment\u2010experienced cirrhotics. For the sofosbuvir\/simeprevir and sofosbuvir\/ledipasvir groups, grade3\/4 haematologic adverse events were uncommon; these trended back close to baseline values after completion of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Sofosbuvir\u2010based regimens in clinical practice are associated with\n                      <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                      rates comparable to those seen in clinical trials and low rates of grade 3\/4 haematological adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.13036","type":"journal-article","created":{"date-parts":[[2015,11,29]],"date-time":"2015-11-29T23:22:39Z","timestamp":1448839359000},"page":"651-658","source":"Crossref","is-referenced-by-count":32,"title":["Sofosbuvir\u2010based regimens in clinical practice achieve\n                    <scp>SVR<\/scp>\n                    rates closer to clinical trials: results from\n                    <scp>ERCHIVES<\/scp>"],"prefix":"10.1111","volume":"36","author":[{"given":"Adeel A.","family":"Butt","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"Hamad Healthcare Quality Institute Doha Qatar"},{"name":"Hamad Medical Corporation Doha Qatar"},{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obaid S.","family":"Shaikh","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Boston MA USA"},{"name":"Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine\/UC Health Cincinnati OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ERCHIVES study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12375"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12546"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir774"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"e_1_2_8_7_1","first-page":"10","article-title":"Simeprevir with peginterferon\/ribavirin for treatment\u2010naive hepatitis C genotype 1 patients in Japan: CONCERTO\u20101, a phase III trial","volume":"14","author":"Hayashi N","year":"2014","journal-title":"J Hepatol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0949-8"},{"key":"e_1_2_8_9_1","unstructured":"BackusL BelperioP ShahoumianT MoleL.Effectiveness of Sofosbuvir\u2010Based Hepatitis C (HCV) Antiviral Regimens in a Large U.S. Veteran Cohort. Digestive Disease Week May 16\u201019 2015 Washington DC 2015."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00885.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/599371"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23000"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02156.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.09.023"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12107"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.023"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27835"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6502"},{"key":"e_1_2_8_19_1","volume-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System","author":"World Health Organization"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1001-25"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099150"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13036","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:22:40Z","timestamp":1695532960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,25]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/liv.13036"],"URL":"https:\/\/doi.org\/10.1111\/liv.13036","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725972392.793512117","asserted-by":"object"}]},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,25]]}}}